Related Experiment Video
Updated: Jan 23, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
Direct Ras G12C inhibitors: crossing the rubicon
Colin R Lindsay1,2,3, Fiona H Blackhall4,5,6
1Division of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, UK. colin.lindsay@manchester.ac.uk.
None:
Despite its status as the most commonly mutated oncogene in cancer, Ras has long been considered 'undruggable'. In 2019, we will see the first clinical trial results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous clinical and biological failures.
Related Concept Videos
The Ras Gene
Ras is a...
Antihypertensive Drugs: Direct Renin Inhibitors
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Crossing Over
The homologous pairs of sister chromosomes—one from the maternal and one from the paternal genome—then begin to align alongside each other lengthwise, matching corresponding DNA positions in a process...
Crossed Aldol Reaction Using Strong Bases: Directed Aldol Reaction
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

